Literature DB >> 413436

Trifluorothymidine and idoxuridine therapy of ocular herpes.

D Pavan-Langston, C S Foster.   

Abstract

In a coded study, we treated 40 patients who had active herpes simplex corneal ulcers with either 1% trifluorothymidine (F3T) or 0.1% idoxuridine (IDU) drops; we treated 15 similarly afflicted patients, who had failed on IDU or vidarabine, with open 1% F3T drops. All dosages were at therapeutically recommended frequency. In the coded study there was no statistically significant difference between the drugs in rate of healing; mean initial ulcer size in both groups was approximately 7 mm2 and mean healing time was approximately 5.5 days. There was a significant difference, however, in the chances of successful healing; 96% of all F3T treated eyes and only 75% of IDU treated eyes healed completely within 14 days. In the open study, 87% of patients healed completely on F3T eyedrops. Although an insufficient number of patients were on concomitant coricosteroid therapy to provide statistical analysis, F3T-corticosteroid treated eyes (eight masked and open) all healed. The one IDU-corticosteroid treated eye in the masked study failed to heal.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 413436     DOI: 10.1016/0002-9394(77)90504-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  13 in total

1.  Epidemiology and molecular analysis of herpes simplex keratitis requiring primary penetrating keratoplasty.

Authors:  B C Branco; P A Gaudio; T P Margolis
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

Review 2.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2015-01-09

Review 3.  Herpes simplex virus ocular infections: current concepts of acute, latent and reactivated disease.

Authors:  D Pavan-Langston
Journal:  Trans Am Ophthalmol Soc       Date:  1990

4.  Evaluation of a peptidomimetic ribonucleotide reductase inhibitor with a murine model of herpes simplex virus type 1 ocular disease.

Authors:  C R Brandt; B Spencer; P Imesch; M Garneau; R Déziel
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Acyclovir and trifluorothymidine in herpetic keratitis: a multicentre trial.

Authors:  C la Lau; J A Oosterhuis; J Versteeg; G van Rij; J G Renardel de Lavalette; A Craandijk; W P Lamers; W P Lamers
Journal:  Br J Ophthalmol       Date:  1982-08       Impact factor: 4.638

6.  The treatment of herpes simplex virus epithelial keratitis.

Authors:  K R Wilhelmus
Journal:  Trans Am Ophthalmol Soc       Date:  2000

Review 7.  Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.

Authors:  Kirk R Wilhelmus
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

Review 8.  Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1982-05       Impact factor: 9.546

Review 9.  Herpes keratitis.

Authors:  A M Rowe; A J St Leger; S Jeon; D K Dhaliwal; J E Knickelbein; R L Hendricks
Journal:  Prog Retin Eye Res       Date:  2012-08-27       Impact factor: 21.198

10.  Corneal epithelial dysplasia after trifluridine use.

Authors:  P C Maudgal; B Van Damme; L Missotten
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1983       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.